Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024993001> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2024993001 endingPage "S73" @default.
- W2024993001 startingPage "S68" @default.
- W2024993001 abstract "The cardiovascular effects of bradykinin require additional vasoactive mediators for a fully balanced response. This includes arachidonic acid (eicosatetraenoic acid) and its metabolites, the eicosanoids (prostaglandins, leukotrienes, thromboxanes, and others). Eicosanoid generation by bradykinin is started by binding of the peptide to specific B2 receptors at the plasma membrane. This initiates G-protein coupled stimulation of phospholipase C, IP3-induced increases in cytosolic Ca2+, and stimulation of protein kinase C. Arachidonic acid is liberated from membrane phospholipids primarily via Ca(2+)-induced stimulation of phospholipase A2 and converted into tissue-specific eicosanoids by enzymes in the vicinity. In vascular tissue, most of the available arachidonic acid is converted into vasodilator prostaglandins, i.e., prostacyclin (PGI2) and prostaglandin E2 (PGE2). These prostaglandins are involved in vasodilator actions of the kinins. There is also some evidence for generation of vasoconstrictor eicosanoids, such as thromboxane A2, under certain conditions. The biological significance of kinin-related prostaglandin formation becomes apparent after inhibition of kinin breakdown by ACE inhibitors. These compounds prevent generation of vasoconstrictor angiotensin II and stimulate endothelial eicosanoid formation via local kinin accumulation. There is evidence suggesting that kinin-induced prostaglandin generation contributes to anti-ischemic, inotropic, and blood pressure-lowering effects of the compounds. This also includes inhibition of polymorphonuclear leukocyte (PMN) accumulation in injured myocardial tissue, which is antagonized by PGI2-related pathways, stimulated by ACE inhibition and/or bradykinin." @default.
- W2024993001 created "2016-06-24" @default.
- W2024993001 creator A5056255955 @default.
- W2024993001 date "1992-01-01" @default.
- W2024993001 modified "2023-09-28" @default.
- W2024993001 title "Role of Prostaglandins in the Cardiovascular Effects of Bradykinin and Angiotensin-Converting Enzyme Inhibitors" @default.
- W2024993001 doi "https://doi.org/10.1097/00005344-199200209-00013" @default.
- W2024993001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1282633" @default.
- W2024993001 hasPublicationYear "1992" @default.
- W2024993001 type Work @default.
- W2024993001 sameAs 2024993001 @default.
- W2024993001 citedByCount "58" @default.
- W2024993001 countsByYear W20249930012013 @default.
- W2024993001 countsByYear W20249930012014 @default.
- W2024993001 countsByYear W20249930012017 @default.
- W2024993001 crossrefType "journal-article" @default.
- W2024993001 hasAuthorship W2024993001A5056255955 @default.
- W2024993001 hasConcept C126322002 @default.
- W2024993001 hasConcept C134018914 @default.
- W2024993001 hasConcept C170493617 @default.
- W2024993001 hasConcept C181199279 @default.
- W2024993001 hasConcept C185592680 @default.
- W2024993001 hasConcept C2776246183 @default.
- W2024993001 hasConcept C2776352991 @default.
- W2024993001 hasConcept C2776551241 @default.
- W2024993001 hasConcept C2778078955 @default.
- W2024993001 hasConcept C2779591629 @default.
- W2024993001 hasConcept C2780664492 @default.
- W2024993001 hasConcept C2781024287 @default.
- W2024993001 hasConcept C2781128415 @default.
- W2024993001 hasConcept C2908929049 @default.
- W2024993001 hasConcept C2909278008 @default.
- W2024993001 hasConcept C55493867 @default.
- W2024993001 hasConcept C71924100 @default.
- W2024993001 hasConcept C86803240 @default.
- W2024993001 hasConceptScore W2024993001C126322002 @default.
- W2024993001 hasConceptScore W2024993001C134018914 @default.
- W2024993001 hasConceptScore W2024993001C170493617 @default.
- W2024993001 hasConceptScore W2024993001C181199279 @default.
- W2024993001 hasConceptScore W2024993001C185592680 @default.
- W2024993001 hasConceptScore W2024993001C2776246183 @default.
- W2024993001 hasConceptScore W2024993001C2776352991 @default.
- W2024993001 hasConceptScore W2024993001C2776551241 @default.
- W2024993001 hasConceptScore W2024993001C2778078955 @default.
- W2024993001 hasConceptScore W2024993001C2779591629 @default.
- W2024993001 hasConceptScore W2024993001C2780664492 @default.
- W2024993001 hasConceptScore W2024993001C2781024287 @default.
- W2024993001 hasConceptScore W2024993001C2781128415 @default.
- W2024993001 hasConceptScore W2024993001C2908929049 @default.
- W2024993001 hasConceptScore W2024993001C2909278008 @default.
- W2024993001 hasConceptScore W2024993001C55493867 @default.
- W2024993001 hasConceptScore W2024993001C71924100 @default.
- W2024993001 hasConceptScore W2024993001C86803240 @default.
- W2024993001 hasIssue "Supplement 9" @default.
- W2024993001 hasLocation W20249930011 @default.
- W2024993001 hasLocation W20249930012 @default.
- W2024993001 hasOpenAccess W2024993001 @default.
- W2024993001 hasPrimaryLocation W20249930011 @default.
- W2024993001 hasRelatedWork W1777790898 @default.
- W2024993001 hasRelatedWork W2010638491 @default.
- W2024993001 hasRelatedWork W2024993001 @default.
- W2024993001 hasRelatedWork W2112293469 @default.
- W2024993001 hasRelatedWork W2113023385 @default.
- W2024993001 hasRelatedWork W214321706 @default.
- W2024993001 hasRelatedWork W2218181558 @default.
- W2024993001 hasRelatedWork W3123541770 @default.
- W2024993001 hasRelatedWork W3171802359 @default.
- W2024993001 hasRelatedWork W4325222 @default.
- W2024993001 hasVolume "20" @default.
- W2024993001 isParatext "false" @default.
- W2024993001 isRetracted "false" @default.
- W2024993001 magId "2024993001" @default.
- W2024993001 workType "article" @default.